BioNTech terminates Phase 2 Cevumeran mRNA cancer vaccine trial
- Announcement of trial termination for personalized mRNA candidate BNT122/autogene cevumeran triggered sharp premarket selloff on Aug 28
- Follows recent sector rally (BNTX +22% mid-August) driven by Moderna's positive Phase 3 melanoma mRNA vaccine data
- Investors viewed termination as direct negative read-through after BNTX benefited from competitor validation of mRNA oncology approach
- Comes amid ongoing challenges including lowered 2026 revenue guidance, H1 net loss of €1.35B, and manufacturing restructuring (incl. Singapore site closure)
- Pipeline pivot to other lung cancer assets like pumitamig continues, with WCLC data presentations upcoming in September
- Stock had pulled back from recent highs near $116 prior to today's move
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.